The FDA cleared an investigational new drug application for AVZO-1418/DB-1418, and a phase 1/2 trial in advanced solid tumors ...

Naomi Haas, MD, discusses the 5-year follow-up of the KEYNOTE-564 study being presented at the 2025 ASCO Annual Meeting.

POLB 001 has been granted FDA orphan drug designation as a preventative therapy for cytokine release syndrome caused by ...

Kat M. Aguilar, MPH, discussed findings on social determinants of health and cancer mortality and their practical ...

A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing response rates of almost 50% with 20% complete responses, and offers the ...

A panelist discusses how axatilimab demonstrated efficacy in a heavily pretreated patient population with predominantly severe chronic graft-vs-host disease (cGVHD) in the AGAVE-201 trial, with ...

Dong Chen, MD, PhD, discusses how AI has changed the landscape for genomic testing and patient management. AI has truly revolutionized healthcare, profoundly enhancing both patient management and the ...

Patients with BRCA-altered uterine leiomyosarcoma treated with PARP inhibitors demonstrated encouraging outcomes.

Prof Martin Dreyling discusses the unmet needs in MCL and the potential next lines of research on the BTK inhibitor acalabrutinib.

Panelists discuss how hepcidin mimetics like rusfertide offer a novel approach to managing polycythemia vera (PV) by regulating iron metabolism, reducing iron overload, and improving hematocrit ...

Panelists discuss how clinical trial data has shaped second-line therapy in polycythemia vera (PV), highlighting ruxolitinib and interferon as key options for patients resistant or intolerant to ...

In an interview, Arvind Bussetty, MD, and Arvind Trindade, MD, delved into the rising rates of gastrointestinal cancers among younger patients.